[{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"European Network for Gynaecological Oncological Trial Groups","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"TORL-1-23","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase II","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TORL BioTherapeutics \/ European Network for Gynaecological Oncological Trial Groups","highestDevelopmentStatusID":"8","companyTruncated":"TORL BioTherapeutics \/ European Network for Gynaecological Oncological Trial Groups"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"TORL-1-23","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Translational Research in Oncology"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2024","type":"Series B Financing","leadProduct":"TORL-1-23","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0.16,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2023","type":"Series B Financing","leadProduct":"TORL-1-23","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0.16,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TORL-2-307-ADC","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Translational Research in Oncology"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TORL-2-307-MAB","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Translational Research in Oncology"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TORL-3-600","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Translational Research in Oncology"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TORL-4-500","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Translational Research in Oncology"}]

Find Clinical Drug Pipeline Developments & Deals by TORL BioTherapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Lead Product(s) : TORL-1-23

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : European Network for Gynaecological Oncological Trial Groups

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          November 15, 2024

                          Lead Product(s) : TORL-1-23

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : European Network for Gynaecological Oncological Trial Groups

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The financing will continue clinical development of TORL-1-23, a potentially best-in-class ADC for Claudin 6 positive tumors, through Phase 1 and pivotal Phase 2 trials.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          October 04, 2024

                          Lead Product(s) : TORL-1-23

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Deep Track Capital

                          Deal Size : $158.0 million

                          Deal Type : Series B Financing

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 22, 2023

                          Lead Product(s) : TORL-4-500

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Translational Research In Oncology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 17, 2023

                          Lead Product(s) : TORL-3-600

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Translational Research In Oncology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The net funding will used to advance TORL-1-23, a first-in-class, clinical-stage ADC targeting Claudin 6, TORL-2-307, a clinical-stage ADC targeting Claudin 18.2 and other novel clinical and preclinical stage programs.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          April 13, 2023

                          Lead Product(s) : TORL-1-23

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Goldman Sachs & Co

                          Deal Size : $158.0 million

                          Deal Type : Series B Financing

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 16, 2021

                          Lead Product(s) : TORL-2-307-MAB

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Translational Research In Oncology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 14, 2021

                          Lead Product(s) : TORL-2-307-ADC

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Translational Research In Oncology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          November 02, 2021

                          Lead Product(s) : TORL-1-23

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Translational Research In Oncology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank